SCHEMBL5408914

SCHEMBL5408914

CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]c(C)c(-c3ccc(C(=O)N4CCN(C)CC4)cc3)c1C)C(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.56
SRC P12931 13/20 0.55
KDR P35968 8/20 0.54
FGFR1 P11362 7/20 0.54
CDK2 P24941 3/20 0.54
PTK2B Q14289 2/20 0.54
MEN1 O00255 1/20 0.54
CCNE1 P24864 1/20 0.54
RECQL P46063 1/20 0.54
KMT2A Q03164 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LCK P06239 6/20 0.52
FYN P06241 6/20 0.52
PDGFRB P09619 6/20 0.52
YES1 P07947 5/20 0.52
AURKA O14965 1/20 0.47
CHEK1 O14757 1/20 0.46
ABL1 P00519 1/20 0.46
CSF1R P07333 1/20 0.46
RET P07949 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409928 0.93 MET (0.55) METSRCKDRFGFR1CDK2
SCHEMBL5410121 0.92 KDR (0.56) METSRCKDRFGFR1CDK2
SCHEMBL5419732 0.91 MET (0.59) METSRCKDRFGFR1CDK2
SCHEMBL5421077 0.89 KDR (0.61) METSRCKDRFGFR1CDK2
SCHEMBL29399522 0.88 MET (0.70) METSRCKDRFGFR1CDK2
SCHEMBL5401490 0.84 KDR (0.53) METSRCKDRFGFR1CDK2
SCHEMBL5406599 0.83 MET (0.58) METSRCKDRFGFR1CDK2
SCHEMBL5410956 0.82 KDR (0.59) METSRCKDRFGFR1CDK2
SCHEMBL5396478 0.82 KDR (0.62) METSRCKDRFGFR1CDK2
SCHEMBL14595093 0.81 KDR (0.56) METSRCKDRFGFR1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 MET 2590/4885SRC 297/4885KDR 1657/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM MET 2434/4885SRC 663/4885KDR 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.